BR112021019936A2 - Compostos inibidores de permutador 3 de sódio-hidrogênio - Google Patents
Compostos inibidores de permutador 3 de sódio-hidrogênioInfo
- Publication number
- BR112021019936A2 BR112021019936A2 BR112021019936A BR112021019936A BR112021019936A2 BR 112021019936 A2 BR112021019936 A2 BR 112021019936A2 BR 112021019936 A BR112021019936 A BR 112021019936A BR 112021019936 A BR112021019936 A BR 112021019936A BR 112021019936 A2 BR112021019936 A2 BR 112021019936A2
- Authority
- BR
- Brazil
- Prior art keywords
- sodium
- hydrogen exchanger
- inhibiting compounds
- compound
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 108091006649 SLC9A3 Proteins 0.000 title abstract 3
- 102000046061 Sodium-Hydrogen Exchanger 3 Human genes 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
compostos inibidores de permutador 3 de sódio-hidrogênio. a presente invenção refere-se a compostos inibidores do trocador de sódio-hidrogênio 3 (nhe3) da fórmula: a composições farmacêuticas compreendendo o composto e ao uso do composto para o tratamento de certas doenças associadas a níveis elevados de sódio e/ou fosfato.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848652P | 2019-05-16 | 2019-05-16 | |
| PCT/US2020/031999 WO2020231770A1 (en) | 2019-05-16 | 2020-05-08 | Sodium-hydrogen exchanger 3 inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019936A2 true BR112021019936A2 (pt) | 2021-12-07 |
Family
ID=70919092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019936A BR112021019936A2 (pt) | 2019-05-16 | 2020-05-08 | Compostos inibidores de permutador 3 de sódio-hidrogênio |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220213042A1 (pt) |
| EP (1) | EP3921308B1 (pt) |
| JP (1) | JP7194848B2 (pt) |
| KR (1) | KR20210151911A (pt) |
| CN (1) | CN113784956A (pt) |
| AU (1) | AU2020276204B2 (pt) |
| BR (1) | BR112021019936A2 (pt) |
| CA (1) | CA3136060A1 (pt) |
| EA (1) | EA202192414A1 (pt) |
| ES (1) | ES2927100T3 (pt) |
| IL (1) | IL287963A (pt) |
| MA (1) | MA54900A (pt) |
| MX (1) | MX2021013771A (pt) |
| WO (1) | WO2020231770A1 (pt) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10312963A1 (de) | 2003-03-24 | 2004-10-07 | Aventis Pharma Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| PL2384318T3 (pl) | 2008-12-31 | 2018-04-30 | Ardelyx, Inc. | Związki i sposoby inhibicji mediowanego przez NHE antyportu w leczeniu zaburzeń związanych z retencją płynów lub nadmiarem soli i chorób przewodu pokarmowego |
| WO2014169094A2 (en) | 2013-04-12 | 2014-10-16 | Ardelyx, Inc | Nhe3-binding compounds and methods for inhibiting phosphate transport |
| PL3497091T3 (pl) * | 2016-08-15 | 2021-02-08 | Eli Lilly And Company | Skondensowane pochodne tiofenu, użyteczne jako inhibitory NaPi-IIb |
-
2020
- 2020-05-08 EP EP20729401.8A patent/EP3921308B1/en active Active
- 2020-05-08 ES ES20729401T patent/ES2927100T3/es active Active
- 2020-05-08 CN CN202080033042.9A patent/CN113784956A/zh active Pending
- 2020-05-08 AU AU2020276204A patent/AU2020276204B2/en active Active
- 2020-05-08 US US17/611,456 patent/US20220213042A1/en active Pending
- 2020-05-08 CA CA3136060A patent/CA3136060A1/en active Pending
- 2020-05-08 KR KR1020217036739A patent/KR20210151911A/ko active IP Right Grant
- 2020-05-08 MX MX2021013771A patent/MX2021013771A/es unknown
- 2020-05-08 WO PCT/US2020/031999 patent/WO2020231770A1/en active Application Filing
- 2020-05-08 EA EA202192414A patent/EA202192414A1/ru unknown
- 2020-05-08 JP JP2021565751A patent/JP7194848B2/ja active Active
- 2020-05-08 BR BR112021019936A patent/BR112021019936A2/pt unknown
- 2020-05-08 MA MA054900A patent/MA54900A/fr unknown
-
2021
- 2021-11-09 IL IL287963A patent/IL287963A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113784956A (zh) | 2021-12-10 |
| IL287963A (en) | 2022-01-01 |
| WO2020231770A1 (en) | 2020-11-19 |
| ES2927100T3 (es) | 2022-11-02 |
| JP7194848B2 (ja) | 2022-12-22 |
| CA3136060A1 (en) | 2020-11-19 |
| EP3921308A1 (en) | 2021-12-15 |
| AU2020276204B2 (en) | 2022-05-19 |
| MA54900A (fr) | 2022-03-23 |
| AU2020276204A1 (en) | 2021-10-07 |
| EA202192414A1 (ru) | 2022-03-02 |
| MX2021013771A (es) | 2021-12-10 |
| EP3921308B1 (en) | 2022-08-03 |
| KR20210151911A (ko) | 2021-12-14 |
| US20220213042A1 (en) | 2022-07-07 |
| JP2022531438A (ja) | 2022-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
| BR112019000247A2 (pt) | derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores | |
| BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
| CU20210080A7 (es) | Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa | |
| BR112019024831A2 (pt) | composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 | |
| BR112018007381A2 (pt) | compostos úteis como imunomoduladores | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| UY29360A1 (es) | Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones. | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| BR112022025613A2 (pt) | Novo inibidor de secreção de ácido e uso do mesmo | |
| BR112019024785A2 (pt) | composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso | |
| AR085308A1 (es) | Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea | |
| BR112019007763A2 (pt) | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção | |
| BR112015022092A8 (pt) | derivado de di-hidropiridazina-3,5-diona, seu uso e agente preventivo e/ou terapêutico comprendendo o mesmo | |
| CL2021000843A1 (es) | Inhibidores de pde4 que contienen boro | |
| CL2021002263A1 (es) | Compuestos antibacterianos (solicitud divisional 202001147) | |
| BR112022020147A2 (pt) | Compostos para tratar a doença de huntington | |
| CO2021003391A2 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| BR112021023927A2 (pt) | Composto, e, composição farmacêutica | |
| BR112022025117A2 (pt) | 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1 | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| ECSP22026478A (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
| BR112023019030A2 (pt) | Derivados de fósforo como inibidores de sos1 | |
| BR112022012737A2 (pt) | Composto antagonista de pd-l1 |